Immutep Limited American Depositary Shares - IMMP STOCK NEWS

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has made significant advancements in its clinical development strategy for the quarter ending March 31, 2023. The company initiated the AIPAC-003 Phase II/III trial for eftilagimod alpha (efti) in HER2-negative and triple-negative metastatic breast cancer, with the first patient enrollment expected in Q2 2023. Positive final data from the TACTI-002 trial showed a 39% overall survival rate at 21 months for patients with second-line non-small cell lung cancer (NSCLC). The TACTI-003 trial reached 75% enrollment, and top-line results are anticipated in H2 2023. Furthermore, the INSIGHT-003 trial's expansion aims to evaluate a triple combination therapy in NSCLC. Immutep maintains a robust cash position of A$55.2 million, providing a runway until June 2024.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the presentation of final results from the Phase II TACTI-002 trial, focusing on patients with second-line head and neck squamous cell carcinoma. The results will be showcased at the 2023 ASCO Annual Meeting, which takes place from June 2-6 in Chicago, Illinois. The trial evaluates the combination of eftilagimod alpha and pembrolizumab in patients who are unselected for PD-L1 expression. Additionally, the trial design for the Phase II/III AIPAC-003 study, which tests eftilagimod alpha in HER2-negative metastatic breast cancer, will also be presented. Key presentation details include poster sessions on June 4 and 5. This opportunity allows Immutep to engage with leading oncology experts and gain visibility for its innovative therapies.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has appointed Florian D. Vogl, M.D., Ph.D., MSc, as its new Chief Medical Officer, effective May 1, 2023. Dr. Vogl brings over a decade of biopharmaceutical experience, particularly in oncology, having previously served as CMO at Cellestia Biotech and held senior roles at Rainier Therapeutics, Novartis, and Amgen. He is recognized for his expertise in clinical strategy and regulatory affairs in both the U.S. and Europe. Dr. Vogl succeeds Frédéric Triebel, who will now focus solely on his role as Chief Scientific Officer. Immutep aims to advance its late-stage clinical pipeline in oncology and its pre-clinical program in autoimmune diseases under Dr. Vogl's leadership. The company is known for its LAG-3 immunotherapy portfolio, including the promising candidate, eftilagimod alpha, which has shown encouraging efficacy and safety in treating various solid tumors.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has initiated an open-label Phase II trial evaluating eftilagimod alpha (efti) in combination with pembrolizumab and radiotherapy for treating soft tissue sarcoma (STS). This study marks the first time efti is tested in a neoadjuvant setting, aiming to address the high unmet medical need for STS patients, who have limited treatment options. Funded primarily by the Maria Skłodowska-Curie National Research Institute of Oncology, the trial will include up to 40 patients. Results may provide insights into the immune response generated by this novel triple combination therapy. Efti's mechanism involves activating antigen-presenting cells, potentially enhancing anti-tumor immunity. The first patient dosing is expected in the first half of 2023.

Immutep Limited (NASDAQ: IMMP) has released positive final data from the TACTI-002 Phase II trial, focusing on 2nd line metastatic non-small cell lung cancer patients who are refractory to anti-PD-(L)1 therapy. The combination of eftilagimod alpha and pembrolizumab yielded a median overall survival (mOS) of 9.9 months and a 39% overall survival rate at 21 months, outperforming standard chemotherapy outcomes. The trial demonstrated a tumor shrinkage or deceleration in growth in 83% of patients. The combination therapy showed an objective response rate of 8.3% and a disease control rate of 33.3%, with favorable tolerance and no new safety signals.

Immutep (ASX: IMM; NASDAQ: IMMP) has announced the expansion of its INSIGHT-003 trial to 50 patients, following successful safety and efficacy results for its combination therapy involving eftilagimod alpha (efti), anti-PD-1 therapy, and chemotherapy in treating 1st line non-small cell lung cancer (1L NSCLC). The initial enrolment reached 20 patients, and additional data is expected throughout 2023. Early results show an overall response rate (ORR) of 72.7% and a disease control rate (DCR) of 90.9%. This trial aims to assess the potential of efti to address the entire NSCLC patient population.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced new data from the TACTI-002 Phase II trial focusing on 2nd line non-small cell lung cancer (NSCLC) patients who are refractory to anti-PD-(L)1 therapy. The trial included 36 patients showing promising results with an Overall Response Rate (ORR) of 8.3% and a 33% Disease Control Rate (DCR). Additionally, 83% of patients experienced tumor growth deceleration or shrinkage. Final safety and efficacy data, including Overall Survival (OS) metrics, will be presented at the European Lung Cancer Congress (ELCC) 2023 in Copenhagen from March 29 to April 1.